Study Purpose:Routine MRI is normal in motor neuron diseases such as ALS. However, advanced MRI techniques can provide an objective measure of degeneration (a "biomarker") by examining brain structure, wiring, chemistry, and function. We will develop and evaluate novel MRI techniques that could improve our understanding of ALS and provide a means to diagnose it sooner and monitor its progression. Importantly, we expect these techniques to improve how new drugs are tested, which may lead to the more rapid discovery of a treatment for ALS.
Each participant will have 3 MRI scans over a period of 8 months, along with neurological and cognitive evaluations. Study visits will take 2 - 3 hours. MRI is a safe technique that does not involve radiation.
Amyotrophic Lateral Sclerosis , Motor Neuron Disease
Type of Intervention:
Study Chair(s)/Principal Investigator(s):
Sanjay Kalra, MD, FRCPC
Coordinating Center Contact Information
University of Alberta
Full Study Summary:
CALSNIC was founded with the objective to validate MRI biomarkers on a standardized multi-centre platform. CALSNIC is a multidisciplinary group of scientists at 7 centres across Canada. The first CALSNIC study entitled "MRI Biomarkers in ALS" (CALSNIC-1) is ongoing and slated to finish recruitment in 2017.
This study ("Novel MRI Biomarkers for Monitoring Disease Progression in ALS", CALSNIC-2) is a new project that will evaluate novel MRI biomarkers using advanced imaging acquisition and processing methods. The specific aims of CALSNIC-2 are 1) to establish a standardized MRI and clinical protocol across the 7 centres, and 2) to validate MRI measures with clinical measures of disease burden and progression.
It is anticipated that the project will lead to the discovery of MR-based biomarkers of cerebral degeneration that can be applied across different centres and hence, can assist with drug development. Secondly, this project will expand CALSNIC to include more centres and provide opportunities for collaborative and multidisciplinary translational research on a national scale.
University of Alberta
Estimated Study Start Date:
10 / 01 / 2016
Estimated Study Completion Date:
12 / 01 / 2022
Posting Last Modified Date:
08 / 11 / 2022
Date Study Added to neals.org:
12 / 05 / 2017
Can participants use Riluzole?
- Patients with a suspected or confirmed diagnosis as described in Study Populations
- For those with a diagnosis of ALS, patients will be considered with an El Escorial classification of suspected, possible, probable, probable lab-supported, and definite ALS.
- Patients 18 years of age or older
- Healthy controls over the age of 40.
- Be able to lie in an MRI machine for approximately 60 minutes
- Subjects with psychiatric/CNS illnesses such as Major Depressive Disorder, Schizophrenia, and Bipolar disorder.
- Subjects with significant head injury or other neurological disease (stroke, brain tumour).
- Subjects ineligible for MRI investigation due to a pacemaker or other metallic foreign body.
University of Miami | Recruiting
University of Utah | Recruiting
Salt Lake City, Utah
University of Calgary / Heritage Medical Research Clinic | Recruiting
University of Alberta | Recruiting
University of British Columbia / GF Strong Rehab Centre | Withdrawn
Vancouver, British Columbia
Western University / London Health Sciences Centre | Withdrawn
University of Toronto / Sunnybrook Health Sciences Centre | Recruiting
McGill University / Montreal Neurological Institute and Hospital | Recruiting
Laval University | Recruiting
Quebec City, Quebec